Durlobactam-Sulbactam Therapy for Resistant Acinetobacter Pneumonia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The increasing resistance of Acinetobacter baumannii isolates to current β-lactamase inhibitors, such as sulbactam, limits treatment options for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, necessitating alternative therapies.

Innovation Solution

The use of durlobactam, optionally combined with sulbactam, to treat pneumonia caused by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex, with dosages adjusted based on creatinine clearance rates, administered intravenously.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If sulbactam is used as a β-lactamase inhibitor to treat Acinetobacter baumannii infections, then treatment options are provided, but resistance increases and clinical efficacy decreases

Engineering Contradiction:

Improvetreatment optionsVSAvoidclinical efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent introduces durlobactam, a novel β-lactamase inhibitor with a different chemical structure and mechanism of action compared to sulbactam. This parameter change in the inhibitor class allows effective treatment of Acinetobacter baumannii infections while overcoming the resistance issue that limits sulbactam efficacy.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If colistin is used to treat Acinetobacter baumannii infections, then treatment effectiveness is achieved, but nephrotoxicity occurs

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidnephrotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses durlobactam as an intermediary substance that inhibits β-lactamase enzymes, thereby protecting the patient from nephrotoxicity while maintaining treatment effectiveness against Acinetobacter baumannii infections.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If β-lactamase inhibitors are used to counter β-lactamases, then antibiotic effectiveness is improved, but resistance to inhibitors increases

Engineering Contradiction:

Improveantibiotic effectivenessVSAvoidresistance diversity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs durlobactam, which has a distinct chemical structure and inhibition mechanism compared to traditional β-lactamase inhibitors like sulbactam. This parameter change enables effective counteraction of diverse β-lactamases while avoiding the resistance problem that arises with repeated use of conventional inhibitors.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250352553A1Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of acinetobacter baumannii-calcoaceticus complex

Publication Date: 2025.11.20 ENTASIS THERAPEUTICS INC

AI summary

Provided are methods of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex using durlobactam and sulbactam.